ABOUT 7th_IOIF
> REGISTRATION
​​> AGENDA
​​> PRESENTERS
​​> ATTENDEES
​​> INVESTORS
> SPONSORS
​​> SUPPORTERS
> NETWORKING

​> ABOUT ​LAST YEAR

spotlight presenters

BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to identify patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO).

https://www.bergenbio.com/

CYTOVIA THERAPEUTICS

Cytovia aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available Natural Killer cell therapy as a first line of defense against cancer. Cytovia’s proprietary multi-specific antibody platform has been customized to engage and activate NK Cells at the tumor site. Both platforms offer optionality to clinicians and can also be used synergistically. Cytovia’s R&D laboratories and GMP manufacturing facility are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, STC Biologics, and the University of California San Francisco (UCSF).

​www.cytoviatx.com

Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase 2 clinical trials.
​
https://www.markertherapeutics.com/

Phosplatin Therapeutics Inc.

Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia. It holds the exclusive, global license to phosphaplatins, a family of novel agents currently in clinical development for the treatment of both solid tumors and hematological cancers. Phosphaplatins are the result of over 20 years of work by the inventor, and uniquely combine an immunological form of apoptosis with an attractive safety profile. The lead agent is the subject of two approved IND applications with the US FDA, and of a collaboration and option agreement for rights in Greater China with SciClone Pharmaceuticals.

www.phosplatin.com

Ultimovacs ASA

Ultimovacs (Euronext Oslo Stock Exchange: ULTI.OL) is a Norwegian biotech Company that is pursuing several Phase II clinical development trials in a number of cancer indications. The company is advancing its proprietary peptide-based universal cancer vaccine program, UV1. UV1 induces a specific T cell response against the universal cancer antigen telomerase (hTERT) and is made up of long, synthetic peptides shown to induce CD4+ T cells displaying a Th1 cytokine profile. With over 85% of tumors expressing hTERT at a high level, UV1 has the potential to treat a broad range of cancer indications.

To date, Ultimovacs has conducted multiple Phase I studies in different cancer indications with different inhibitor combinations, confirming the safety and tolerability of its proprietary vaccine. The company announced the initiation of four Phase II triple combination studies.

ultimovacs.com

20-minute showcases

APEIRON Biologics AG

APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies and respiratory treatments.

Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.

APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.

​www.apeiron-biologics.com

Apogenix AG

Apogenix is developing innovative biotherapeutics for the treatment of cancer and viral infections. The lead candidate asunercept has demonstrated significant efficacy in glioblastoma and MDS clinical studies. A pivotal phase II/III study for glioblastoma is planned. Two phase II studies in COVID-19 patients will start in Q3/2020.

Apogenix’ scientific team has developed the HERA-ligand technology platform. The first candidate – TRAIL receptor agonist ABBV-621 is out-licensed to Abbvie. Phase I studies are ongoing in solid and hemato-oncological indications.

​apogenix.com/en/

Ashvattha Therapeutics

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel hydroxyl dendrimer (HD) therapeutics (HDTs) to treat unmet medical needs in oncology, ophthalmology, and inflammatory diseases. We believe that HDTs will become the future of targeted therapeutics and unlock new levels of patient care.

avttx.com

Domain Therapeutics SA

Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and early development of new drug candidates targeting transmembrane receptors, in particular, G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. Domain identifies and develops candidates (allosteric modulators and biased ligands) through its innovative approach and technologies. Domain has three revenue-generating pillars within its innovative business model: 1) collaboration with pharma companies for the discovery of new molecules 2) out-licensing of its bioSens-All™ technology and 3) creation of asset-centric vehicles for the development of its internal pipeline of preclinical candidates for central nervous system disorders, cancer and rare diseases. These asset-centric companies attract investment for focused development and exit is through a trade sale at an appropriate inflection point. ​

​https://www.domaintherapeutics.com/

eTheRNA immunotherapies NV

eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases. We employ messenger RNA to unleash and boost a patient’s immune response against a tumor or infectious agent. Research shows that this approach results in long lasting clinical remission in cancer patients and protective immunity against infections.

eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology.

www.etherna.be/

Geneos Therapeutics

At Geneos, our passion is to develop personalized therapies to unleash the most powerful force against cancer – your body’s own immune system. Our GT-EPIC Platform is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor specific neoantigen-targeted personalized immunotherapies.

​www.geneostx.com

Imagia

Imagia’s mission is to leverage advances in artificial intelligence and accelerate the advent of accessible personalized medicine.

We believe that synergies between academia, institutions and commercial partners are a critical success factor in the quest towards precision medicine.

​imagia.com

IMV Inc.

At IMV, we believe that everyone deserves effective cancer treatments that respect patients’ quality of life. Our unique DPX technology gives us the ability to create a new class of immunotherapy that generates targeted and long-lasting immune activation with limited side effects. With this unique ability, we are dedicated to improving cancer treatment and giving everyone a chance to enjoy a long and healthy life.  

​www.imv-inc.com

IO Biotech ApS

IO Biotech is a clinical stage biotech company developing disruptive immune modulating anti-cancer therapies. We are focused on the development of immunological treatment of cancer with a research profile based on successful R&D discoveries, translated into numerous clinical trials.

IO Biotech has achieved a proven track record of progressing pre-clinical and clinical compounds:

• Two lead anti-cancer therapies targeting IDO and PD-L1 are in clinical development
• Several compounds finalizing the preclinical phase

IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board. IO Biotech is a privately held company with a solid financial position funded by experienced investors: Lundbeckfonden Emerge, Novo Seeds & Sunstone. 
IO Biotech is located in Copenhagen, Denmark and was founded in December 2014 as a spin-out from the Centre for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital, Denmark. CCIT provides the infrastructure of certified clinical grade laboratory for preparation of therapeutic products.

​www.iobiotech.com

NOXXON Pharma NV

NOXXON’s oncology-focused pipeline acts by neutralizing chemokines in the tumor micro-environment (TME). NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact.

www.noxxon.com/

OSE Immunotherapeutics

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

​ose-immuno.com/en/

PharmAbcine, Inc.

PharmAbcine Inc. is a bio venture specialized in R&D of antibody treatment in the clinical stage and currently possesses core technologies such as potent antibody development technology using potent non-immune scFv phage display library, new-generation double target antibody production technology, and antibody production technology using cancer stem cell library. Since we were established in 2008 we have been devoted to developing new cancer antibody drugs and laying a foundation for TTAC-0001 and PMC-001. We will constantly develop pipelines for sustainable growth with a vision to release a new global blockbuster bio drug by 2020 and become a global bioengineering company.

​www.pharmabcine.com

Refuge Biotechnologies, Inc.

Refuge is a cancer immunotherapy company leveraging synthetic biology and gene engineering to unlock the full promise of cell therapies. We create cell therapies that sense their surroundings and conditionally activate or repress multiple genes simultaneously – resulting in more potent and targeted treatments beyond a single target and function.

​refugebiotech.com

VAXIMM

VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.
​
VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor and it can be readily adapted to target a wide range of cancer-related antigens.
https://vaximm.com/

10-minute showcases

Exactis Innovation

Founded in 2014, Exactis Innovation (Exactis) is a Business-Led Networks Centres of Excellence (BL-NCE) that comprises a pan-Canadian Network of 14 oncology centers that brings together public and private partners focusing on precision oncology research.

www.exactis.ca

Treos Bio Ltd.

Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in patients predicted by our diagnostic tests to respond.

​treosbio.com